| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
UTP-13C9,15N2 sodium does not have a specific biological target as it is an analytical internal standard. The parent compound, UTP, is a substrate for RNA polymerases in RNA synthesis and is involved in various metabolic pathways, including the synthesis of UDP-sugars for glycosylation reactions.
|
|---|---|
| ln Vitro |
UTP-13C9,15N2 sodium does not exhibit pharmacological activity as it is used exclusively as an analytical standard. Its utility is in enabling accurate quantification of UTP in biological samples by mass spectrometry. The compound exhibits identical chromatographic and mass spectrometric behavior to UTP.
|
| ln Vivo |
UTP-13C9,15N2 sodium is not used as a therapeutic agent and does not exhibit in vivo activity. It is administered as an internal standard in metabolic studies to accurately quantify UTP concentrations.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not performed for UTP-13C9,15N2 sodium, as it is an analytical standard. Its characterization involves analytical method validation, including assessment of its chromatographic behavior and mass spectrometric response.
|
| Cell Assay |
In vitro cellular assays are not applicable to UTP-13C9,15N2 sodium, as it is an analytical standard used for quantification purposes. The compound is spiked into biological samples to serve as an internal standard for LC-MS/MS or other mass spectrometry-based methods.
|
| Animal Protocol |
In vivo animal experiments for UTP-13C9,15N2 sodium involve administering the compound alongside UTP in metabolic studies. Biological samples are collected, and UTP concentrations are measured by mass spectrometry using the labeled internal standard for normalization.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for UTP-13C9,15N2 sodium are not separately characterized, as it is used as an internal standard for measuring UTP levels. It enables accurate quantification of UTP in pharmacokinetic and metabolic studies.
|
| Toxicity/Toxicokinetics |
Toxicological data for UTP-13C9,15N2 sodium are not separately evaluated, as it is used in trace amounts as an analytical internal standard. The compound is for research use only.
|
| Additional Infomation |
Uridine triphosphate-13C9,15N2 sodium (UTP-13C9,15N2 sodium; Uridine 5'-triphosphate-13C9,15N2 sodium) (CAS#: 285978-18-9) is a stable isotope-labeled internal standard for UTP quantification by mass spectrometry. The compound is for research use only.
|
| Molecular Formula |
13C9H1315N2NA2O15P3
|
|---|---|
| Molecular Weight |
539.03
|
| Exact Mass |
527.932
|
| CAS # |
285978-18-9
|
| Related CAS # |
Uridine triphosphate;63-39-8
|
| PubChem CID |
75487599
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
31
|
| Complexity |
828
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)([O-])OP(=O)(O)OP(=O)(O)[O-])O)O.[Na+].[Na+]
|
| InChi Key |
JFXKPFPIFSFLOU-WFIJOQBCSA-L
|
| InChi Code |
InChI=1S/C9H15N2O15P3.2Na/c12-5-1-2-11(9(15)10-5)8-7(14)6(13)4(24-8)3-23-28(19,20)26-29(21,22)25-27(16,17)18;;/h1-2,4,6-8,13-14H,3H2,(H,19,20)(H,21,22)(H,10,12,15)(H2,16,17,18);;/q;2*+1/p-2/t4-,6-,7-,8-;;/m1../s1
|
| Chemical Name |
disodium;[[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : 125 mg/mL (231.90 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (185.52 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8552 mL | 9.2759 mL | 18.5518 mL | |
| 5 mM | 0.3710 mL | 1.8552 mL | 3.7104 mL | |
| 10 mM | 0.1855 mL | 0.9276 mL | 1.8552 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
